1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Neurodegenerative Diseases in 61 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
Neurodegenerative Diseases: Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Creatine, however, was still neuroprotective in mice, which were deficient in mitochondrial creatine kinase." | 2.47 | Neuroprotective effects of creatine. ( Beal, MF, 2011) |
| "Mangiferin (MGF) is a glucosyl xanthone mainly derived from Mangifera indica L." | 1.72 | Mangiferin, a natural glucoxilxanthone, inhibits mitochondrial dynamin-related protein 1 and relieves aberrant mitophagic proteins in mice model of Parkinson's disease. ( Chen, NH; Feng, ST; Guo, ZY; Wang, XL; Wang, YT; Wang, ZZ; Yan, X; Yuan, YH; Zhang, NN; Zhang, Y, 2022) |
| "Studies on Parkinson's disease patients and dopamine-depleted animals indicate that dopaminergic neurons in the retina degenerate due to the genetic and environmental factors that cause dopaminergic neuron loss in the substantia nigra." | 1.37 | Minor retinal degeneration in Parkinson's disease. ( Huang, YM; Yin, ZQ, 2011) |
| "Hydrogen sulfide (H(2)S) has been shown to protect neurons." | 1.37 | Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson's disease. ( Ichinose, F; Kakinohana, M; Kaneki, M; Kida, K; Marutani, E; Tokuda, K; Yamada, M, 2011) |
| " Here, we show that drinking H(2)-containing water significantly reduced the loss of dopaminergic neurons in PD model mice using both acute and chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.35 | Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. ( Fujita, K; Katafuchi, T; Kido, MA; Nakabeppu, Y; Noda, M; Ohno, M; Sakumi, K; Seike, T; Takaki, A; Tanaka, Y; Yamada, H; Yamaguchi, H; Yamakawa, Y; Yutsudo, N, 2009) |
| "Tolcapone treatment enhanced CSF DOPAC concentrations in unlesioned animals (by approximately four times) as well as monkeys rendered parkinsonian after severe nigrostriatal dopaminergic injury caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.32 | Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration. ( Di Monte, DA; Langston, JW; Thiffault, C, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (8.20) | 18.2507 |
| 2000's | 15 (24.59) | 29.6817 |
| 2010's | 15 (24.59) | 24.3611 |
| 2020's | 26 (42.62) | 2.80 |
| Authors | Studies |
|---|---|
| Park, JE | 1 |
| Leem, YH | 1 |
| Park, JS | 1 |
| Kim, DY | 1 |
| Kang, JL | 1 |
| Kim, HS | 1 |
| Su, Y | 1 |
| Liu, N | 1 |
| Zhang, Z | 2 |
| Li, H | 1 |
| Ma, J | 2 |
| Yuan, Y | 1 |
| Shi, M | 1 |
| Liu, J | 2 |
| Zhao, Z | 2 |
| Holscher, C | 1 |
| Kang, SS | 1 |
| Wu, Z | 1 |
| Liu, X | 2 |
| Edgington-Mitchell, L | 1 |
| Ye, K | 2 |
| Wang, SM | 1 |
| Wang, Q | 1 |
| Ye, LY | 1 |
| Chen, SX | 1 |
| Tao, L | 1 |
| Yang, ZS | 1 |
| Xu, B | 1 |
| Wang, X | 1 |
| Xu, Z | 2 |
| Li, Q | 1 |
| Quan, J | 1 |
| Wang, XL | 1 |
| Feng, ST | 1 |
| Wang, YT | 1 |
| Zhang, NN | 1 |
| Guo, ZY | 1 |
| Yan, X | 1 |
| Yuan, YH | 1 |
| Wang, ZZ | 1 |
| Chen, NH | 1 |
| Zhang, Y | 1 |
| Wang, L | 1 |
| Wu, X | 1 |
| Yang, G | 1 |
| Hu, N | 1 |
| Zhao, L | 1 |
| Li, S | 1 |
| Wu, Y | 1 |
| Liu, H | 1 |
| Wang, Y | 6 |
| Sheng, H | 1 |
| Chen, Z | 1 |
| Xun, D | 1 |
| Wu, H | 1 |
| Xiao, S | 1 |
| Bi, Y | 1 |
| D'Amico, R | 1 |
| Impellizzeri, D | 1 |
| Genovese, T | 1 |
| Fusco, R | 1 |
| Peritore, AF | 1 |
| Crupi, R | 1 |
| Interdonato, L | 1 |
| Franco, G | 1 |
| Marino, Y | 1 |
| Arangia, A | 1 |
| Gugliandolo, E | 1 |
| Cuzzocrea, S | 1 |
| Di Paola, R | 1 |
| Siracusa, R | 1 |
| Cordaro, M | 1 |
| He, D | 1 |
| Liu, Y | 1 |
| Li, J | 1 |
| Wang, H | 2 |
| Ye, B | 1 |
| He, Y | 1 |
| Li, Z | 1 |
| Gao, X | 1 |
| Fu, S | 1 |
| Liu, D | 1 |
| Guo, Y | 1 |
| Huang, H | 1 |
| Xu, J | 1 |
| Jiang, C | 1 |
| Chang, N | 1 |
| Ge, Q | 1 |
| Wang, G | 1 |
| Zhao, X | 1 |
| Jiang, Z | 3 |
| Yin, X | 3 |
| Wang, M | 3 |
| Li, F | 3 |
| Gao, Y | 3 |
| Han, G | 3 |
| Gao, Z | 3 |
| Wang, Z | 3 |
| Presti-Silva, SM | 2 |
| Herlinger, AL | 2 |
| Martins-Silva, C | 2 |
| Pires, RGW | 2 |
| Sun, T | 2 |
| Chen, L | 1 |
| Liu, R | 1 |
| Liu, QS | 2 |
| Cheng, Y | 2 |
| Aktas, B | 1 |
| Briñez-Gallego, P | 1 |
| da Costa Silva, DG | 1 |
| Cordeiro, MF | 1 |
| Horn, AP | 1 |
| Hort, MA | 1 |
| Pu, Z | 1 |
| Liu, S | 1 |
| Guo, Z | 1 |
| Zhang, X | 1 |
| Yan, J | 1 |
| Tang, Y | 1 |
| Xiao, H | 1 |
| Gao, J | 1 |
| Li, Y | 1 |
| Bai, Q | 1 |
| Khanal, S | 1 |
| Bok, E | 1 |
| Kim, J | 1 |
| Park, GH | 1 |
| Choi, DY | 1 |
| Menshchikova, EB | 1 |
| Khrapova, MV | 1 |
| Kozhin, PM | 1 |
| Chechushkov, AV | 1 |
| Serykh, AE | 1 |
| Romakh, LP | 1 |
| Kandalintseva, NV | 1 |
| Pan, T | 1 |
| Xiao, Q | 1 |
| Fan, HJ | 1 |
| Xu, L | 1 |
| Qin, SC | 1 |
| Yang, LX | 1 |
| Jin, XM | 1 |
| Xiao, BG | 1 |
| Zhang, B | 1 |
| Ma, CG | 1 |
| Chai, Z | 1 |
| Lian, C | 1 |
| Pan, L | 1 |
| Lai, W | 1 |
| Zhang, F | 1 |
| Peng, L | 1 |
| Zhou, S | 1 |
| Zhao, G | 1 |
| Yang, X | 1 |
| Zhang, G | 1 |
| Tan, Z | 1 |
| Heo, EJ | 1 |
| Lee, Y | 2 |
| Hyung Seo, M | 1 |
| Yeo, S | 1 |
| Mei, M | 1 |
| Zhou, Y | 1 |
| Liu, M | 1 |
| Zhao, F | 1 |
| Wang, C | 2 |
| Ding, J | 1 |
| Lu, M | 1 |
| Hu, G | 1 |
| Ding, ZX | 1 |
| Luo, X | 1 |
| Dionísio, PA | 1 |
| Amaral, JD | 1 |
| Rodrigues, CMP | 1 |
| Jeon, H | 1 |
| Bae, CH | 1 |
| Kim, HY | 1 |
| Kim, S | 1 |
| Liu, W | 1 |
| Chen, Y | 1 |
| Liu, P | 1 |
| Hayashi, T | 1 |
| Mizuno, K | 1 |
| Hattori, S | 1 |
| Fujisaki, H | 1 |
| Ikejima, T | 1 |
| Schildknecht, S | 1 |
| Di Monte, DA | 2 |
| Pape, R | 1 |
| Tieu, K | 1 |
| Leist, M | 1 |
| Singh, B | 1 |
| Pandey, S | 1 |
| Yadav, SK | 1 |
| Verma, R | 1 |
| Singh, SP | 1 |
| Mahdi, AA | 1 |
| Xu, SF | 1 |
| Zhang, YH | 1 |
| Wang, S | 1 |
| Pang, ZQ | 1 |
| Fan, YG | 1 |
| Li, JY | 1 |
| Wang, ZY | 1 |
| Guo, C | 1 |
| Whittemore, K | 1 |
| Derevyanko, A | 1 |
| Martinez, P | 1 |
| Serrano, R | 1 |
| Pumarola, M | 1 |
| Bosch, F | 1 |
| Blasco, MA | 1 |
| Tristão, FS | 1 |
| Amar, M | 1 |
| Latrous, I | 1 |
| Del-Bel, EA | 1 |
| Prediger, RD | 1 |
| Raisman-Vozari, R | 1 |
| Iqbal, S | 1 |
| Howard, S | 1 |
| LoGrasso, PV | 1 |
| Weng, JC | 1 |
| Tikhonova, MA | 1 |
| Chen, JH | 1 |
| Shen, MS | 1 |
| Meng, WY | 1 |
| Chang, YT | 1 |
| Chen, KH | 1 |
| Liang, KC | 1 |
| Hung, CS | 1 |
| Amstislavskaya, TG | 1 |
| Ho, YJ | 2 |
| Wu, AG | 1 |
| Zeng, W | 1 |
| Wong, VK | 1 |
| Zhu, YZ | 1 |
| Lo, AC | 1 |
| Liu, L | 1 |
| Law, BY | 1 |
| Kakefuda, K | 1 |
| Fujita, Y | 1 |
| Oyagi, A | 1 |
| Hyakkoku, K | 1 |
| Kojima, T | 1 |
| Umemura, K | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Ito, M | 1 |
| Nozawa, Y | 1 |
| Hara, H | 1 |
| Fujita, K | 1 |
| Seike, T | 1 |
| Yutsudo, N | 1 |
| Ohno, M | 1 |
| Yamada, H | 1 |
| Yamaguchi, H | 1 |
| Sakumi, K | 1 |
| Yamakawa, Y | 1 |
| Kido, MA | 1 |
| Takaki, A | 1 |
| Katafuchi, T | 1 |
| Tanaka, Y | 1 |
| Nakabeppu, Y | 1 |
| Noda, M | 1 |
| Huang, YM | 1 |
| Yin, ZQ | 1 |
| Kida, K | 1 |
| Yamada, M | 1 |
| Tokuda, K | 1 |
| Marutani, E | 1 |
| Kakinohana, M | 1 |
| Kaneki, M | 1 |
| Ichinose, F | 1 |
| Beal, MF | 4 |
| Kim, SS | 1 |
| Lim, J | 1 |
| Bang, Y | 1 |
| Gal, J | 1 |
| Lee, SU | 1 |
| Cho, YC | 1 |
| Yoon, G | 1 |
| Kang, BY | 1 |
| Cheon, SH | 1 |
| Choi, HJ | 1 |
| Hsieh, MH | 1 |
| Gu, SL | 1 |
| Ho, SC | 1 |
| Pawlak, CR | 1 |
| Lin, CL | 1 |
| Lai, TJ | 1 |
| Wu, FY | 1 |
| Bian, M | 1 |
| Hong, X | 1 |
| Yu, M | 1 |
| Huang, Y | 1 |
| Sheng, Z | 1 |
| Fei, J | 1 |
| Huang, F | 1 |
| Cole, GM | 1 |
| Vila, M | 1 |
| Przedborski, S | 1 |
| Thiffault, C | 1 |
| Langston, JW | 1 |
| Castagnoli, N | 1 |
| Petzer, JP | 1 |
| Steyn, S | 1 |
| Castagnoli, K | 1 |
| Chen, JF | 1 |
| Schwarzschild, MA | 1 |
| Van der Schyf, CJ | 1 |
| Klivenyi, P | 2 |
| Starkov, AA | 1 |
| Calingasan, NY | 1 |
| Gardian, G | 1 |
| Browne, SE | 1 |
| Yang, L | 1 |
| Bubber, P | 1 |
| Gibson, GE | 1 |
| Patel, MS | 1 |
| Virmani, A | 1 |
| Gaetani, F | 1 |
| Binienda, Z | 1 |
| Gal, S | 1 |
| Zheng, H | 1 |
| Fridkin, M | 1 |
| Youdim, MB | 1 |
| Sacksteder, CA | 1 |
| Qian, WJ | 1 |
| Knyushko, TV | 1 |
| Chin, MH | 1 |
| Lacan, G | 1 |
| Melega, WP | 1 |
| Camp, DG | 1 |
| Smith, RD | 1 |
| Smith, DJ | 1 |
| Squier, TC | 1 |
| Bigelow, DJ | 1 |
| Navneet, AK | 1 |
| Appukuttan, TA | 1 |
| Pandey, M | 1 |
| Mohanakumar, KP | 1 |
| Brochier, C | 1 |
| Gaillard, MC | 1 |
| Diguet, E | 1 |
| Caudy, N | 1 |
| Dossat, C | 1 |
| Ségurens, B | 1 |
| Wincker, P | 1 |
| Roze, E | 1 |
| Caboche, J | 1 |
| Hantraye, P | 1 |
| Brouillet, E | 1 |
| Elalouf, JM | 1 |
| de Chaldée, M | 1 |
| Schulz, JB | 1 |
| Matthews, RT | 1 |
| Klockgether, T | 1 |
| Dichgans, J | 1 |
| Smith, TS | 2 |
| Bennett, JP | 2 |
| Trimmer, PA | 1 |
| Khan, SM | 1 |
| Tinklepaugh, DL | 1 |
| Lan, J | 1 |
| Jiang, DH | 1 |
| Ho, A | 1 |
| Blum, M | 1 |
| Heumann, R | 1 |
| Goemans, C | 1 |
| Bartsch, D | 1 |
| Lingenhöhl, K | 1 |
| Waldmeier, PC | 1 |
| Hengerer, B | 1 |
| Allegrini, PR | 1 |
| Schellander, K | 1 |
| Wagner, EF | 1 |
| Arendt, T | 1 |
| Kamdem, RH | 1 |
| Obst-Pernberg, K | 1 |
| Narz, F | 1 |
| Wahle, P | 1 |
| Berns, H | 1 |
| Andreassen, OA | 1 |
| Ferrante, RJ | 1 |
| Dedeoglu, A | 1 |
| Albers, DW | 1 |
| Carlson, EJ | 1 |
| Epstein, CJ | 1 |
| Dryhurst, G | 1 |
8 reviews available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Neurodegenerative Diseases
| Article | Year |
|---|---|
Experimental models of chemically induced Parkinson's disease in zebrafish at the embryonic larval stage: a systematic review.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Larva; Models | 2023 |
Oxidative stress and regulated cell death in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2021 |
Tipping Points and Endogenous Determinants of Nigrostriatal Degeneration by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Dopaminergic Neurons; Humans; MPT | 2017 |
Neuroprotective effects of creatine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Creatine; Humans; Neurodegenerative Diseases; | 2011 |
Targeting programmed cell death in neurodegenerative diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Anim | 2003 |
Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: metabolic inhibitors, MPTP, and methamphetamine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antimetabolites; Antioxidants; Carnitine; Cen | 2005 |
The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Hydr | 1997 |
Are dopamine, norepinephrine, and serotonin precursors of biologically reactive intermediates involved in the pathogenesis of neurodegenerative brain disorders?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Diseases; Dopamine; Dopamine Uptake Inh | 2001 |
53 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Neurodegenerative Diseases
| Article | Year |
|---|---|
Anti-Inflammatory and Neuroprotective Mechanisms of GTS-21, an α7 Nicotinic Acetylcholine Receptor Agonist, in Neuroinflammation and Parkinson's Disease Mouse Models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti | 2022 |
Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and α-synuclein accumulation in the colon of two Parkinson's disease mouse models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cholecystokinin; Colon; Dise | 2022 |
Treating Parkinson's Disease via Activation of BDNF/TrkB Signaling Pathways and Inhibition of Delta-Secretase.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Amyloid Precursor Protein Secretases; | 2022 |
Effects of hCG on DA neuronal death of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chorionic Gonadotropin; Disease Models, Anima | 2022 |
N-cystaminylbiguanide MC001 prevents neuron cell death and alleviates motor deficits in the MPTP-model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cysteamine; Disease Models, Anima | 2022 |
Mangiferin, a natural glucoxilxanthone, inhibits mitochondrial dynamin-related protein 1 and relieves aberrant mitophagic proteins in mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Disease Models, Anima | 2022 |
Cannabidiol Alleviates the Damage to Dopaminergic Neurons in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson's Disease Mice Via Regulating Neuronal Apoptosis and Neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cannabidiol; Disease Models, Anima | 2022 |
DiHuangYin decoction protects dopaminergic neurons in a Parkinson's disease model by alleviating peripheral inflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Açai Berry Mitigates Parkinson's Disease Progression Showing Dopaminergic Neuroprotection via Nrf2-HO1 Pathways.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Disease Progression; | 2022 |
Isoalantolactone (IAL) Regulates Neuro-Inflammation and Neuronal Apoptosis to Curb Pathology of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Infla | 2022 |
Defining Specific Cell States of MPTP-Induced Parkinson's Disease by Single-Nucleus RNA Sequencing.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Endothelial Cells; Mi | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
Biochemical and behavioral effects of rosmarinic acid treatment in an animal model of Parkinson's disease induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Mice; Mice, | 2023 |
Biochemical and behavioral effects of rosmarinic acid treatment in an animal model of Parkinson's disease induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Mice; Mice, | 2023 |
Biochemical and behavioral effects of rosmarinic acid treatment in an animal model of Parkinson's disease induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Mice; Mice, | 2023 |
Biochemical and behavioral effects of rosmarinic acid treatment in an animal model of Parkinson's disease induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Mice; Mice, | 2023 |
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Disease Models, Animal; Dopaminergic Ne | 2023 |
Gut Microbial Alteration in MPTP Mouse Model of Parkinson Disease is Administration Regimen Dependent.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Casein Reactivates Dopaminergic Nerve Injury and Intestinal Inflammation with Disturbing Intestinal Microflora and Fecal Metabolites in a Convalescent Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caseins; Disease Models, Animal; Dopamine; Ga | 2023 |
Dopaminergic neuroprotective effects of inosine in MPTP-induced parkinsonian mice via brain-derived neurotrophic factor upregulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Dopamine; | 2023 |
Protective Effect of a New Monophenolic Antioxidant TS-13 in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Disease Models, Animal; Mice; M | 2023 |
Wuzi Yanzong Pill relieves MPTP-induced motor dysfunction and neuron loss by inhibiting NLRP3 inflammasome-mediated neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2023 |
N-acetyl-L-leucine protects MPTP-treated Parkinson's disease mouse models by suppressing Desulfobacterota via the gut-brain axis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Gut Axis; Disease Models, Animal; Dopam | 2023 |
Association between SGK1 and α-synuclein in skeletal muscle in an MPTP-induced Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Dopa | 2023 |
Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Blood | 2019 |
Blood Exosomes Have Neuroprotective Effects in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopaminergic N | 2020 |
Korean red ginseng suppresses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced inflammation in the substantia nigra and colon.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Colon; Disease Models, Animal; Dopaminergic N | 2021 |
Silibinin attenuates motor dysfunction in a mouse model of Parkinson's disease by suppression of oxidative stress and neuroinflammation along with promotion of mitophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2021 |
Role of ethanolic extract of Bacopa monnieri against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced mice model via inhibition of apoptotic pathways of dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Bacopa; Disease Models, Animal; Do | 2017 |
Lactoferrin ameliorates dopaminergic neurodegeneration and motor deficits in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Behavior, Animal; Cell Line; Disea | 2019 |
Telomerase gene therapy ameliorates the effects of neurodegeneration associated to short telomeres in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dependovirus; Disease Models, Animal; | 2019 |
Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Corpus Striatum; | 2014 |
Serum- and Glucocorticoid-Inducible Kinase 1 Confers Protection in Cell-Based and in In Vivo Neurotoxin Models via the c-Jun N-Terminal Kinase Signaling Pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cell Line, Tumor; Dopaminergic Ne | 2015 |
Ceftriaxone prevents the neurodegeneration and decreased neurogenesis seen in a Parkinson's disease rat model: An immunohistochemical and MRI study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Brain; Brain Mapping; B | 2016 |
Hederagenin and α-hederin promote degradation of proteins in neurodegenerative diseases and improve motor deficits in MPTP-mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenylate Kinase; alpha-Synuclein; Animals; Autophagy; | 2017 |
Sirtuin 1 overexpression mice show a reference memory deficit, but not neuroprotection.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Ischemia; Memory Disorders; Mice; Mice, | 2009 |
Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Hydrogen; L | 2009 |
Minor retinal degeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Hallucinations; Haplorhini; Humans; | 2011 |
Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Inhalation; Animals; Apoptosis; Base S | 2011 |
Licochalcone E activates Nrf2/antioxidant response element signaling pathway in both neuronal and microglial cells: therapeutic relevance to neurodegenerative disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidant Respons | 2012 |
Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Brain; Disease Models, | 2012 |
Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Dopamine; Dopaminergic Neuro | 2012 |
Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Animals; Clioquinol; Ferritins; Gen | 2003 |
Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2003 |
Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Disease Mo | 2003 |
Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Cell Count; Cerebral Cortex; | 2004 |
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amines; Animals; Brain; Corpus Striatum; Dopamine; Dru | 2005 |
Endogenously nitrated proteins in mouse brain: links to neurodegenerative disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Sequence; Animals; Brain; Capillary Action; | 2006 |
Taurine fails to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Corpus Striatum; Disease Models, Anima | 2008 |
Quantitative gene expression profiling of mouse brain regions reveals differential transcripts conserved in human and affected in disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Conserved Sequence; Databases, Genetic | 2008 |
Mitochondrial toxins in models of neurodegenerative diseases. I: In vivo brain hydroxyl radical production during systemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Azides; Brain; Disease Models, Animal; Dopami | 1997 |
Mitochondrial toxins in models of neurodegenerative diseases. II: Elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Corpus Striatum; Disease Model | 1997 |
Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Stem; Corpus Striatum; Glutathio | 1997 |
Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Cell Death; Corpus Striatum; Denervati | 1998 |
Transgenic activation of Ras in neurons promotes hypertrophy and protects from lesion-induced degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Axotomy; Brain; | 2000 |
Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Carrier Prote | 2001 |